Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile

Robert B Diasio, J. P. Sommadossi, D. S. Cross, W. J. Huster, R. B. Diasio

Research output: Contribution to journalArticle

630 Citations (Scopus)

Abstract

Kinetics of 5-fluorouracil (FUra) and FUra metabolites in plasma and urine were investigated in 10 cancer patients following i.v. bolus administration of 500 mg/m2 FUra with 600 μCi of [6-3H]FUra. Biliary excretion was examined in two patients with external biliary catheters. Quantitation of unchanged drug and metabolites was assessed by a highly specific high-performance liquid chromatographic method. FUra plasma levels declined rapidly with an apparent elimination half-life of 12.9 ± 7.3 min. Dihydrofluorouracil was detected within 5 min in most patients, demonstrating rapid catabolism and reached maximum peak levels of 23.7 ± 9.9 μM at approximately 60 min. The apparent elimination half-life of dihydrofluorouracil (61.9 ± 39.0 min) was consistently greater than that of the unchanged drug. The apparent elimination half-lives of the subsequent metabolites α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine were prolonged with values of 238.9 ± 175.4 min and 1976 ± 358 min, respectively. Approximately 60-90% of the administered dose was excreted in urine within 24 hr, primarily as α-fluoro-β-alanine. Biliary excretion accounted for 2-3% of total administered radioactivity. The major fraction of this radioactivity eluted on high-performance liquid chromatography as a previously unrecognized FUra metabolite. Analysis of its structure is currently ongoing in our laboratory. In conclusion, this study provides the first comprehensive analysis of the formation and excretion of FUra metabolites in plasma, urine, and bile following i.v. bolus administration of FUra in humans.

Original languageEnglish (US)
Pages (from-to)2203-2206
Number of pages4
JournalCancer Research
Volume47
Issue number8
StatePublished - 1987
Externally publishedYes

Fingerprint

Bile
Fluorouracil
Pharmacokinetics
Urine
Alanine
Radioactivity
Half-Life
Pharmaceutical Preparations
Catheters
High Pressure Liquid Chromatography
Acids
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diasio, R. B., Sommadossi, J. P., Cross, D. S., Huster, W. J., & Diasio, R. B. (1987). Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Research, 47(8), 2203-2206.

Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. / Diasio, Robert B; Sommadossi, J. P.; Cross, D. S.; Huster, W. J.; Diasio, R. B.

In: Cancer Research, Vol. 47, No. 8, 1987, p. 2203-2206.

Research output: Contribution to journalArticle

Diasio, RB, Sommadossi, JP, Cross, DS, Huster, WJ & Diasio, RB 1987, 'Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile', Cancer Research, vol. 47, no. 8, pp. 2203-2206.
Diasio, Robert B ; Sommadossi, J. P. ; Cross, D. S. ; Huster, W. J. ; Diasio, R. B. / Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. In: Cancer Research. 1987 ; Vol. 47, No. 8. pp. 2203-2206.
@article{802406c532d74dc08fe6b279513ca2e2,
title = "Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile",
abstract = "Kinetics of 5-fluorouracil (FUra) and FUra metabolites in plasma and urine were investigated in 10 cancer patients following i.v. bolus administration of 500 mg/m2 FUra with 600 μCi of [6-3H]FUra. Biliary excretion was examined in two patients with external biliary catheters. Quantitation of unchanged drug and metabolites was assessed by a highly specific high-performance liquid chromatographic method. FUra plasma levels declined rapidly with an apparent elimination half-life of 12.9 ± 7.3 min. Dihydrofluorouracil was detected within 5 min in most patients, demonstrating rapid catabolism and reached maximum peak levels of 23.7 ± 9.9 μM at approximately 60 min. The apparent elimination half-life of dihydrofluorouracil (61.9 ± 39.0 min) was consistently greater than that of the unchanged drug. The apparent elimination half-lives of the subsequent metabolites α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine were prolonged with values of 238.9 ± 175.4 min and 1976 ± 358 min, respectively. Approximately 60-90{\%} of the administered dose was excreted in urine within 24 hr, primarily as α-fluoro-β-alanine. Biliary excretion accounted for 2-3{\%} of total administered radioactivity. The major fraction of this radioactivity eluted on high-performance liquid chromatography as a previously unrecognized FUra metabolite. Analysis of its structure is currently ongoing in our laboratory. In conclusion, this study provides the first comprehensive analysis of the formation and excretion of FUra metabolites in plasma, urine, and bile following i.v. bolus administration of FUra in humans.",
author = "Diasio, {Robert B} and Sommadossi, {J. P.} and Cross, {D. S.} and Huster, {W. J.} and Diasio, {R. B.}",
year = "1987",
language = "English (US)",
volume = "47",
pages = "2203--2206",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile

AU - Diasio, Robert B

AU - Sommadossi, J. P.

AU - Cross, D. S.

AU - Huster, W. J.

AU - Diasio, R. B.

PY - 1987

Y1 - 1987

N2 - Kinetics of 5-fluorouracil (FUra) and FUra metabolites in plasma and urine were investigated in 10 cancer patients following i.v. bolus administration of 500 mg/m2 FUra with 600 μCi of [6-3H]FUra. Biliary excretion was examined in two patients with external biliary catheters. Quantitation of unchanged drug and metabolites was assessed by a highly specific high-performance liquid chromatographic method. FUra plasma levels declined rapidly with an apparent elimination half-life of 12.9 ± 7.3 min. Dihydrofluorouracil was detected within 5 min in most patients, demonstrating rapid catabolism and reached maximum peak levels of 23.7 ± 9.9 μM at approximately 60 min. The apparent elimination half-life of dihydrofluorouracil (61.9 ± 39.0 min) was consistently greater than that of the unchanged drug. The apparent elimination half-lives of the subsequent metabolites α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine were prolonged with values of 238.9 ± 175.4 min and 1976 ± 358 min, respectively. Approximately 60-90% of the administered dose was excreted in urine within 24 hr, primarily as α-fluoro-β-alanine. Biliary excretion accounted for 2-3% of total administered radioactivity. The major fraction of this radioactivity eluted on high-performance liquid chromatography as a previously unrecognized FUra metabolite. Analysis of its structure is currently ongoing in our laboratory. In conclusion, this study provides the first comprehensive analysis of the formation and excretion of FUra metabolites in plasma, urine, and bile following i.v. bolus administration of FUra in humans.

AB - Kinetics of 5-fluorouracil (FUra) and FUra metabolites in plasma and urine were investigated in 10 cancer patients following i.v. bolus administration of 500 mg/m2 FUra with 600 μCi of [6-3H]FUra. Biliary excretion was examined in two patients with external biliary catheters. Quantitation of unchanged drug and metabolites was assessed by a highly specific high-performance liquid chromatographic method. FUra plasma levels declined rapidly with an apparent elimination half-life of 12.9 ± 7.3 min. Dihydrofluorouracil was detected within 5 min in most patients, demonstrating rapid catabolism and reached maximum peak levels of 23.7 ± 9.9 μM at approximately 60 min. The apparent elimination half-life of dihydrofluorouracil (61.9 ± 39.0 min) was consistently greater than that of the unchanged drug. The apparent elimination half-lives of the subsequent metabolites α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine were prolonged with values of 238.9 ± 175.4 min and 1976 ± 358 min, respectively. Approximately 60-90% of the administered dose was excreted in urine within 24 hr, primarily as α-fluoro-β-alanine. Biliary excretion accounted for 2-3% of total administered radioactivity. The major fraction of this radioactivity eluted on high-performance liquid chromatography as a previously unrecognized FUra metabolite. Analysis of its structure is currently ongoing in our laboratory. In conclusion, this study provides the first comprehensive analysis of the formation and excretion of FUra metabolites in plasma, urine, and bile following i.v. bolus administration of FUra in humans.

UR - http://www.scopus.com/inward/record.url?scp=0023187085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023187085&partnerID=8YFLogxK

M3 - Article

C2 - 3829006

AN - SCOPUS:0023187085

VL - 47

SP - 2203

EP - 2206

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -